Cargando…
RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma
Melanoma remains a major cause of morbidity and mortality worldwide, however tremendous advances have been made in its treatment over the past several years. The discovery of genomic alterations that contribute to oncogenicity has ushered in a new era of molecularly-targeted therapy. Importantly, ov...
Autores principales: | Reuben, Alexandre, Amaria, Rodabe N, Cooper, Zachary A, Wargo, Jennifer A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731654/ https://www.ncbi.nlm.nih.gov/pubmed/29250602 http://dx.doi.org/10.4172/2376-0427.1000139 |
Ejemplares similares
-
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014) -
Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014) -
Update on use of aldesleukin for treatment of high-risk metastatic melanoma
por: Amaria, Rodabe N, et al.
Publicado: (2015) -
Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014) -
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets
Publicado: (1982)